Sickle-Cell Crisis — Vaso-Occlusive, Acute Chest & Exchange Transfusion

Overview & definition

Sickle-cell disease (SCD) is a single-point-mutation haemoglobinopathy that turns deoxygenated haemoglobin into a rigid polymer — one base swap (β6 glutamate→valine) produces HbS, which on deoxygenation stacks into fibres, sickles the red cell, and occludes the microvasculature. The result is two parallel injuries: vaso-occlusion (the pain and the organ infarction) and haemolysis (the chronic anaemia).^[1]

Acute chest syndrome is the leading cause of death, and the ICU exists to stop a painful crisis becoming a chest crisis. The triggers are the ones that shorten the polymerisation delay time — hypoxia, dehydration, infection, cold, acidosis, stress — and the job is to reverse them fast.^[4]

SCD is the most common severe monogenic disorder worldwide and is caused by a single point mutation in the β-globin gene (HBB) on chromosome 11 — a GAG→GTG transversion producing glutamic-acid-to-valine at the sixth position of β-globin (β6 Glu→Val, E6V). The disease is inherited autosomal recessively. The genotype determines the clinical severity: HbSS (sickle cell anaemia, most severe), HbSβ⁰-thalassaemia (no normal β-chain, severe), HbSβ⁺-thalassaemia (reduced normal β-chain, moderate), and HbSC (milder but can still develop ACS and stroke). The sickle-cell trait (HbAS) is asymptomatic under normal conditions — sickling only with extreme hypoxia (severe altitude, unpressurised aircraft, overwhelming sepsis) — and is protective against falciparum malaria, which explains the gene frequency across sub-Saharan Africa, the Mediterranean, the Middle East, and parts of India.^[1][6]

The clinical hallmark is the episodic acute crisis superimposed on chronic haemolytic anaemia and progressive end-organ damage. The crises are: vaso-occlusive pain (commonest), acute chest syndrome (leading cause of death), splenic sequestration (children), aplastic crisis (parvovirus B19), haemolytic crisis, stroke, priapism, and hepatic sequestration. Chronic complications include functional asplenia (El Hoss: the spleen functionally declines, with pneumococcal overwhelming-sepsis risk especially in early childhood), pulmonary hypertension (an independent risk factor for death), chronic kidney disease, avascular necrosis of the femoral head, leg ulcers, retinopathy (HbSC), and silent cerebral infarcts (cognitive decline). The modern ICU goal is not only to manage the acute crisis but to recognise and reverse the triggers and to institute disease-modifying therapy (hydroxycarbamide, and where appropriate the newer anti-P-selectin and HbS-polymerisation-inhibitor drugs).^[1][6]

References32ShowHide

1. [1]Piel FB, Steinberg MH, Rees DC Sickle Cell Disease N Engl J Med, 2017.PMID 28423290
2. [2]Charache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia N Engl J Med, 1995.PMID 7715639
3. [3]Adams RJ, McKie VC, Hsu L, et al. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography N Engl J Med, 1998.PMID 9647873
4. [4]Vichinsky EP, Neumayr LD, Earles AN, et al. Causes and outcomes of the acute chest syndrome in sickle cell disease. National Acute Chest Syndrome Study Group N Engl J Med, 2000.PMID 10861320
5. [5]Gladwin MT, Sachdev V, Jison ML, et al. Pulmonary hypertension as a risk factor for death in patients with sickle cell disease N Engl J Med, 2004.PMID 14985486
6. [6]Yawn BP, Buchanan GR, Afenyi-Annan AN, et al. Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members JAMA, 2014.PMID 25203083
7. [7]DeBaun MR, Gordon MJ, McKinstry RC, et al. Controlled trial of transfusions for silent cerebral infarcts in sickle cell anemia N Engl J Med, 2014.PMID 25140956
8. [13]Biller E, Zhao Y, Berg M, et al. Red blood cell exchange in patients with sickle cell disease-indications and management: a review and consensus report by the therapeutic apheresis subsection of the AABB Transfusion, 2018.PMID 30198607
9. [14]Miller ST How I treat acute chest syndrome in children with sickle cell disease Blood, 2011.PMID 21406723
10. [15]Neumayr L, Lennette E, Kelly D, et al. Mycoplasma disease and acute chest syndrome in sickle cell disease Pediatrics, 2003.PMID 12837872
11. [16]Adams RJ, McKie VC, Brambilla D, et al. Stroke prevention trial in sickle cell anemia Controlled Clinical Trials, 1998.PMID 9492971
12. [17]Pegelow CH Stroke in children with sickle cell anaemia: aetiology and treatment Paediatr Drugs, 2001.PMID 11437187
13. [18]El Hoss S, Brousse V Considering the spleen in sickle cell disease Expert Rev Hematol, 2019.PMID 31195851
14. [19]Zayed AM, Almohaimeed S, Alotaibi T, et al. Splenic sequestration crisis in children with sickle cell disease in the Eastern region of Saudi Arabia BMC Pediatr, 2025.PMID 40887585
15. [20]Chou ST, Alsawas M, Fasano RM, et al. American Society of Hematology 2020 guidelines for sickle cell disease: transfusion support Blood Adv, 2020.PMID 31985807
16. [21]Brandow AM, Carroll CP, Creary S, et al. American Society of Hematology 2020 guidelines for sickle cell disease: management of acute and chronic pain Blood Adv, 2020.PMID 32559294
17. [22]Salonia A, Eardley I, Giuliano F, et al. European Association of Urology guidelines on priapism Eur Urol, 2014.PMID 24314827
18. [23]Chalmers AW, Shammo JM Evaluation of a new tablet formulation of deferasirox to reduce chronic iron overload after long-term blood transfusions Ther Clin Risk Manag, 2016.PMID 26929633
19. [24]Wang WC, Ware RE, Miller ST, et al. Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG) Lancet, 2011.PMID 21571150
20. [25]Brower RG, Matthay MA, Morris A, et al. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome N Engl J Med, 2000.PMID 10793162
21. [26]Guérin C, Reignier J, Richard JC, et al. Prone positioning in severe acute respiratory distress syndrome N Engl J Med, 2013.PMID 23688302
22. [27]Papazian L, Forel JM, Gacouin A, et al. Neuromuscular blockers in early acute respiratory distress syndrome N Engl J Med, 2010.PMID 20843245
23. [28]Frat JP, Thille AW, Mercat A, et al. High-flow oxygen through nasal cannula in acute hypoxemic respiratory failure N Engl J Med, 2015.PMID 25981908
24. [29]Combes A, Hajage D, Capellier G, et al. Extracorporeal Membrane Oxygenation for Severe Acute Respiratory Distress Syndrome N Engl J Med, 2018.PMID 29791822
25. [30]Charuluxananan S, Kyokong O, Somboonviboon W, et al. Ondansetron for treatment of intrathecal morphine-induced pruritus after cesarean delivery Reg Anesth Pain Med, 2000.PMID 11009242
26. [31]Maxwell LG, Kaufmann SC, Bitzer S, et al. The effects of a small-dose naloxone infusion on opioid-induced side effects and analgesia in children and adolescents treated with intravenous patient-controlled analgesia: a double-blind, prospective, randomized, controlled study Anesth Analg, 2005.PMID 15781505
27. [32]Niihara Y, Miller ST, Kanter J, et al. A Phase 3 Trial of L-Glutamine in Sickle Cell Disease N Engl J Med, 2018.PMID 30021096
28. [8]Ware RE, Davis BR, Schultz WH, et al. Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia-TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial Lancet, 2016.PMID 26670617
29. [9]Ataga KI, Kutlar A, Kanter J, et al. Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Disease N Engl J Med, 2017.PMID 27959701
30. [10]Vichinsky E, Hoppe CC, Ataga KI, et al. A Phase 3 Randomized Trial of Voxelotor in Sickle Cell Disease N Engl J Med, 2019.PMID 31199090
31. [11]Bellet PS, Kalinyak KA, Shukla R, Gelfand MJ, Rucknagel DL Incentive spirometry to prevent acute pulmonary complications in sickle cell diseases N Engl J Med, 1995.PMID 7637747
32. [12]Steinberg MH, McCarthy WF, Castro O, et al. The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: A 17.5 year follow-up Am J Hematol, 2010.PMID 20513116